Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Mon, 20.07.2026
CEL-SCI Corporation
Company Name:
CEL-SCI Corporation
ISIN:
US1508376076
Reason for the research:
Update
Recommendation:
Buy
from:
20.07.2026
Target price:
15.00
Target price on sight of:
12 months
Last rating change:
Analyst:
Christian Orquera
First Berlin Equity Research has published a research update on CEL-SCI Corporation (ISIN: US150837607 [ … ]
Mon, 20.07.2026
Marinomed Biotech AG
Company Name:
Marinomed Biotech AG
ISIN:
ATMARINOMED6
Reason for the research:
Update
Recommendation:
Under Review
from:
20.07.2026
Target price:
Under Review
Target price on sight of:
n.a.
Last rating change:
20.07.2026, Formerly Buy
Analyst:
Alexander Rihane
First Berlin Equity Research hat ein Research Update zu Marinomed B [ … ]
Mon, 20.07.2026
Marinomed Biotech AG
Company Name:
Marinomed Biotech AG
ISIN:
ATMARINOMED6
Reason for the research:
Update
Recommendation:
Under Review
from:
20.07.2026
Target price:
Under Review
Target price on sight of:
n.a.
Last rating change:
20.07.2026, Formerly Buy
Analyst:
Alexander Rihane
First Berlin Equity Research hat ein Research Update zu Marinomed B [ … ]
Wed, 15.07.2026
LAIQON AG
Company Name:
LAIQON AG
ISIN:
DE000A12UP29
Reason for the research:
Update
Recommendation:
BUY
from:
15.07.2026
Target price:
€8.70
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Christian Orquera
First Berlin Equity Research has published a research update on LAIQON AG (ISIN: DE000A12UP29). Analyst Ch [ … ]
Mon, 13.07.2026
Northwest Biotherapeutics Inc.
Company Name:
Northwest Biotherapeutics Inc.
ISIN:
US66737P6007
Reason for the research:
Update
Recommendation:
Buy
from:
13.07.2026
Target price:
USD 1.00
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Christian Orquera
First Berlin Equity Research has published a research update on Northwest Biotherapeuti [ … ]
Tue, 30.06.2026
MaaT Pharma SACA
Company Name:
MaaT Pharma SACA
ISIN:
FR0012634822
Reason for the research:
Update
Recommendation:
Under review
from:
30.06.2026
Target price:
Under review
Target price on sight of:
-
Last rating change:
-
Analyst:
Christian Orquera
First Berlin Equity Research has published a research update on MaaT Pharma SACA (ISIN: FR001263 [ … ]
Mon, 22.06.2026
Formycon AG
Company Name:
Formycon AG
ISIN:
DE000A1EWVY8
Reason for the research:
Update
Recommendation:
Buy
from:
22.06.2026
Target price:
€50
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Simon Scholes
First Berlin Equity Research has published a research update on Formycon AG (ISIN: DE000A1EWVY8). Analyst Simo [ … ]
Mon, 15.06.2026
LAIQON AG
Company Name:
LAIQON AG
ISIN:
DE000A12UP29
Reason for the research:
Update
Recommendation:
BUY
from:
15.06.2026
Target price:
€8.70
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Christian Orquera
First Berlin Equity Research has published a research update on LAIQON AG (ISIN: DE000A12UP29). Analyst Ch [ … ]
Thu, 11.06.2026
MaaT Pharma SACA
Company Name:
MaaT Pharma SACA
ISIN:
FR0012634822
Reason for the research:
Update
Recommendation:
Under review
from:
11.06.2026
Target price:
Under review
Target price on sight of:
-
Last rating change:
-
Analyst:
Christian Orquera
First Berlin Equity Research has published a research update on MaaT Pharma SACA (ISIN: FR001263 [ … ]
Mon, 08.06.2026
LAIQON AG
Company Name:
LAIQON AG
ISIN:
DE000A12UP29
Reason for the research:
Update
Recommendation:
BUY
from:
08.06.2026
Target price:
€8.70
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Christian Orquera
First Berlin Equity Research has published a research update on LAIQON AG (ISIN: DE000A12UP29). Analyst Ch [ … ]
